Idiopathic Inflammatory Myopathies
- The idiopathic inflammatory myopathies (dermatomyositis, polymyositis, and overlapping subtypes) are autoimmune, immune-mediated muscle diseases characterised by SYMMETRIC PROXIMAL muscle WEAKNESS (trouble rising from a chair, climbing stairs, lifting overhead) with a raised CREATINE KINASE; according to PubMed, two-thirds of adults have a chronic course and they require MULTIDISCIPLINARY management.
- DERMATOMYOSITIS adds characteristic SKIN signs - the violaceous periorbital HELIOTROPE rash and GOTTRON'S PAPULES over the knuckles (also the shawl/V sign and mechanic's hands) - and is a complement-mediated, interferon-driven microangiopathy; POLYMYOSITIS has the myopathy WITHOUT the skin signs and is a diagnosis of exclusion (inclusion-body myositis and dystrophies must be excluded).
- Two SYSTEMIC ASSOCIATIONS are critical: in adults, dermatomyositis is strongly PARANEOPLASTIC, so a new diagnosis mandates a SEARCH for occult MALIGNANCY; and INTERSTITIAL LUNG DISEASE is a major, sometimes severe, complication (especially with the anti-synthetase syndrome and anti-MDA5 antibodies) - autoantibodies help identify these high-risk subtypes.
- DIAGNOSIS integrates the clinical picture with MYOSITIS-SPECIFIC and -associated ANTIBODIES (which define subtypes and predict complications such as cancer or ILD), ELECTROMYOGRAPHY, MRI (muscle oedema, and a guide to biopsy site), MUSCLE BIOPSY, and elevated muscle enzymes - the antibody profile increasingly guides classification and risk stratification.
- JUVENILE DERMATOMYOSITIS is distinguished by a prominent VASCULOPATHY and the development of CALCINOSIS (dystrophic calcium deposits in skin/soft tissue) which can ulcerate, become infected, restrict joints and cause significant morbidity - and, with chronic weakness, can lead to joint CONTRACTURES.
- MANAGEMENT is medical and multidisciplinary: CORTICOSTEROIDS with steroid-sparing IMMUNOSUPPRESSION (methotrexate, azathioprine, mycophenolate), INTRAVENOUS IMMUNOGLOBULIN (efficacious, particularly in refractory dermatomyositis), and newer agents targeting the interferon/JAK pathway or B cells; the ORTHOPAEDIC relevance is the management of weakness-related disability, joint CONTRACTURES, and the complications of CALCINOSIS (surgical excision of problematic deposits), always alongside the treating rheumatology/neurology team.
- “Inflammatory myopathies = symmetric PROXIMAL weakness + raised CK. DERMATOMYOSITIS = heliotrope rash + Gottron's papules (skin signs); POLYMYOSITIS = no skin signs (diagnosis of exclusion).
- “Adult DM = PARANEOPLASTIC -> SCREEN for occult malignancy. INTERSTITIAL LUNG DISEASE (anti-synthetase, anti-MDA5) is a major complication. Myositis-specific antibodies define subtypes/risk.
- “Juvenile DM = CALCINOSIS + vasculopathy. Treat with corticosteroids + immunosuppression + IVIG (refractory DM); orthopaedic role = weakness/contractures + excising problematic calcinosis.
Symmetric proximal weakness + raised CK; dermatomyositis adds heliotrope rash + Gottron's papules. Confirm with myositis antibodies, EMG, MRI, biopsy.
Adult dermatomyositis is paraneoplastic - screen for occult malignancy. Interstitial lung disease (anti-synthetase, anti-MDA5) can be severe. Juvenile DM -> calcinosis.
Recognition, Diagnosis & Associations
The inflammatory myopathies present with symmetric proximal muscle weakness and a raised creatine kinase. Dermatomyositis adds the heliotrope rash and Gottron's papules (and shawl/V sign, mechanic's hands); polymyositis has the myopathy without the skin signs and is a diagnosis of exclusion. Two associations are critical: adult DM is paraneoplastic (search for occult malignancy), and interstitial lung disease (especially anti-synthetase syndrome and anti-MDA5) can be severe. Diagnosis uses myositis-specific antibodies (which define subtypes and predict cancer/ILD risk), EMG, MRI (oedema; biopsy guide) and muscle biopsy. Juvenile DM features a vasculopathy and calcinosis.
| Feature | Dermatomyositis | Polymyositis |
|---|---|---|
| Skin signs | Yes - heliotrope rash, Gottron's papules | No characteristic skin signs |
| Pathology | Complement-mediated microangiopathy (perifascicular) | T-cell-mediated endomysial |
| Malignancy (adult) | Strong paraneoplastic association - screen | Weaker association |
| Juvenile form | Yes (calcinosis, vasculopathy) | Rare |
| Caveat | Amyopathic form (skin only) | Diagnosis of exclusion (exclude IBM, dystrophy) |
Management & Orthopaedic Relevance
- Medical (mainstay): corticosteroids with steroid-sparing immunosuppression (methotrexate, azathioprine, mycophenolate); IVIG (efficacious, particularly in refractory dermatomyositis); newer interferon/JAK-pathway and B-cell-targeted therapies in refractory disease.
- Screen and treat the associations: malignancy work-up in adult DM; assess/treat interstitial lung disease.
- Orthopaedic relevance: rehabilitation for weakness; prevent/manage joint contractures; excise problematic CALCINOSIS (ulcerating/infected/joint-restricting deposits, especially in juvenile DM); coordinate perioperative immunosuppression.
- Multidisciplinary: managed with rheumatology/neurology and (where relevant) oncology/respiratory.
The single most important systemic point in adult dermatomyositis is its strong paraneoplastic association: a new diagnosis should prompt an age- and risk-appropriate search for an occult malignancy, because the myositis can be the presenting sign of an underlying cancer (and the myositis-specific antibody profile helps identify the highest-risk patients). The second critical association is interstitial lung disease, which can be rapidly progressive and life-threatening, particularly with the anti-synthetase syndrome and anti-MDA5 antibody, so lung involvement must be actively assessed. For the orthopaedic surgeon, the relevance is mostly the consequences of the disease and its treatment - proximal weakness and disability, joint contractures from chronic weakness, and the calcinosis of juvenile dermatomyositis, whose deposits may ulcerate, become infected or restrict joints and sometimes need surgical excision - all managed alongside the rheumatology/neurology team, with attention to perioperative steroids and immunosuppression.
Evidence & Key Studies
Advances in the classification and management of idiopathic inflammatory myopathies
- The idiopathic inflammatory myopathies are immune-mediated disorders with multisystem involvement and a chronic course in two-thirds of adults; autoantibodies aid identification of disease subtypes and their associated severe complications such as cancer or interstitial lung disease.
- Patients should be managed in a multidisciplinary setting; intravenous immunoglobulin is efficacious in refractory dermatomyositis, improving skin and muscle disease activity.
- Advances include interferon-pathway biomarkers and therapies (anti-interferon monoclonals, JAK inhibitors) and B-cell (CD19 CAR-T) approaches for refractory disease.
Paraneoplastic dermatomyositis secondary to an underlying plasma-cell dyscrasia
- Dermatomyositis is often associated with malignancies; this case was paraneoplastic, secondary to an underlying (smouldering multiple myeloma) plasma-cell dyscrasia, reinforcing the malignancy association.
- Recognition of the dermatomyositis presentation (proximal weakness, skin changes, raised creatine kinase) led to investigation for secondary causes.
- Routine screening for secondary causes/malignancy is recommended as part of the dermatomyositis work-up, to allow early diagnosis before organ damage.
According to PubMed, the multisystem nature, antibody-based subtyping (identifying cancer/ILD risk), chronic course, multidisciplinary management and the efficacy of IVIG in refractory dermatomyositis come from the cited Raaphorst review; the paraneoplastic malignancy association and the recommendation to screen for secondary causes from the cited Meel case. The dermatomyositis skin signs (heliotrope, Gottron's), the polymyositis diagnosis of exclusion, juvenile DM calcinosis, and the orthopaedic relevance (weakness, contracture, calcinosis excision) are standard, well-established teaching. (See also our Musculoskeletal Sarcoidosis, Calcinosis/Tumoral Calcinosis and Inclusion-Body Myositis topics.)
Clinical Decision Scenarios
Practise clinical reasoning and management decisions out loud
“An adult presents with symmetric proximal weakness, a violaceous rash around the eyes and scaly papules over the knuckles. What is the diagnosis and what must you not miss?”
Mnemonics & Memory Aids
MYOSITIS
Hook:MYOSITIS: Malignancy, Young (juvenile/calcinosis), Occult ILD, Symmetric proximal weakness, Immunosuppression+IVIG, Tests, Inflammatory skin (DM), Skin-sparing (PM).
Recognise
- Symmetric proximal muscle weakness + raised creatine kinase
- Dermatomyositis: heliotrope rash, Gottron's papules (shawl/V sign, mechanic's hands)
- Polymyositis: no skin signs (diagnosis of exclusion - exclude IBM/dystrophy)
Critical associations
- Adult dermatomyositis = paraneoplastic -> screen for occult malignancy
- Interstitial lung disease (anti-synthetase syndrome, anti-MDA5) - can be severe
- Juvenile DM: vasculopathy + calcinosis
Diagnosis
- Myositis-specific antibodies (subtype/risk stratification)
- EMG, MRI (oedema, biopsy guide), muscle biopsy
- Elevated muscle enzymes (CK)
Management
- Corticosteroids + steroid-sparing immunosuppression (methotrexate/azathioprine/MMF)
- IVIG (refractory DM); interferon/JAK and B-cell therapies in refractory disease
- Orthopaedic: weakness/contractures; excise problematic calcinosis